Fondazione CNAO, Strada Privata Campeggi, 27100, Pavia, Italy,
Radiol Med. 2014 Apr;119(4):277-82. doi: 10.1007/s11547-013-0345-0. Epub 2013 Dec 12.
The Italian National Centre for Oncological Hadrontherapy (Centro Nazionale di Adroterapia Oncologica, CNAO), equipped with a proton and ion synchrotron, started clinical activity in September 2011. The clinical and technical characteristics of the first ten proton beam radiotherapy treatments are reported.
Ten patients, six males and four females (age range 27-73 years, median 55.5), were treated with proton beam radiotherapy. After one to two surgical procedures, seven patients received a histological diagnosis of chordoma (of the skull base in three cases, the cervical spine in one case and the sacrum in three cases) and three of low-grade chondrosarcoma (skull base). Prescribed doses were 74 GyE for chordoma and 70 GyE for chondrosarcoma at 2 GyE/fraction delivered 5 days per week.
Treatment was well tolerated without toxicity-related interruptions. The maximal acute toxicity was grade 2, with oropharyngeal mucositis, nausea and vomiting for the skull base tumours, and grade 2 dermatitis for the sacral tumours. After 6-12 months of follow-up, no patient developed tumour progression.
The analysis of the first ten patients treated with proton therapy at CNAO showed that this treatment was feasible and safe. Currently, patient accrual into these as well as other approved protocols is continuing, and a longer follow-up period is needed to assess tumour control and late toxicity.
意大利国家肿瘤强子治疗中心(Centro Nazionale di Adroterapia Oncologica,CNAO)配备了质子和离子同步加速器,于 2011 年 9 月开始临床活动。本文报道了前 10 例质子束放射治疗的临床和技术特点。
10 例患者,6 例男性,4 例女性(年龄 27-73 岁,中位数 55.5 岁)接受了质子束放射治疗。在 1 至 2 次手术之后,7 例患者被诊断为脊索瘤(颅底 3 例,颈椎 1 例,骶骨 3 例),3 例为低度软骨肉瘤(颅底)。脊索瘤的处方剂量为 74 GyE,软骨肉瘤的处方剂量为 70 GyE,均为 2 GyE/次,每周 5 次。
治疗耐受性良好,无因毒性而中断治疗。最严重的急性毒性为 2 级,颅底肿瘤为口咽黏膜炎、恶心和呕吐,骶骨肿瘤为 2 级皮炎。随访 6-12 个月后,无患者出现肿瘤进展。
在 CNAO 接受质子治疗的前 10 例患者的分析表明,这种治疗是可行且安全的。目前,正在为这些患者以及其他批准的方案继续招募患者,需要更长的随访时间来评估肿瘤控制和晚期毒性。